San Diego-based CureScience Institute, a non-profit organization dedicated to accelerating novel curative therapies, disclosed on Tuesday that Dr Boris Reznik has been appointed as an Advisory Board member.
Dr Reznik is chairman of Venvalo Group, venture value optimization firm and is a veteran of several startups.
According to CureScience Institute, Dr Reznik has a strong track record of building companies across a diverse set of technologies-based industries, primarily focused on biomedical sciences.
CEO of CureScience Institute, Dr Shashaanka Ashili, commented: "I am delighted to welcome Dr Reznik to our Advisory Board," adding "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr Reznik's counsel as we work towards developing personalized therapeutic approaches."
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Elute partners Spartan Medical
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Abbott's Navitor TAVI system granted CE Mark for expanded indication
PharmaResearch names VIVACY as European distribution partner for Rejuran
Airiver medical receives FDA approval for central airway stenosis trial